Ignite Creation Date:
2025-12-24 @ 7:57 PM
Ignite Modification Date:
2026-03-09 @ 1:59 AM
Study NCT ID:
NCT00543504
Status:
COMPLETED
Last Update Posted:
2020-06-30
First Post:
2007-10-11
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Bevacizumab in Multiple Phase I Combinations
Sponsor:
M.D. Anderson Cancer Center
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Advanced Cancer | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Advanced Cancer | View |
| None | Bevacizumab | View |
| None | Avastin | View |
| None | Sorafenib | View |
| None | BAY 43-9006 | View |
| None | Erlotinib | View |
| None | OSI-774 | View |
| None | Tarceva | View |
| None | Trastuzumab | View |
| None | Herceptin | View |
| None | Sunitinib | View |
| None | SU011248 | View |
| None | Sutent | View |
| None | Cetuximab | View |
| None | Lapatinib | View |
| None | Tykerb | View |
| None | Anti-VEGF monoclonal antibody | View |
| None | rhuMAb-VEGF | View |
| None | Erlotinib hydrochloride | View |
| None | GW572016 | View |
| None | Sunitinib Malate | View |